Alligator Bioscience’s rights issue oversubscribed
Alligator Bioscience AB (publ) (“Alligator” or the “Company”) has completed the share issue with pre-emption rights for the Company’s shareh ...
Larger shareholder and board member transfer subscription rights free of charge to qualified investors
The Board of Directors of Alligator Bioscience AB (publ) (“Alligator” or the “Company”) resolved on December 15, 2020, pursuant to the autho ...
Alligator Bioscience appoints Chief Scientific Officer
Lund, Sweden, January 15, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Peter Ellmark ...
The subscription period in Alligator Bioscience’s rights issue commences today
Today is the first day of the subscription period in Alligator Bioscience AB (publ)’s (“Alligator” or the “Company”) rights issue of shares ...
Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or the "Company") has, in connection with the rights i ...
Alligator Bioscience recruits new Chief Medical Officer
Lund, Sweden, December 29, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Dr Christina ...
Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1
Lund, Sweden, December 28, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has submitted a CTA (Clinical Trial ...
Alligator carries out a fully guaranteed rights issue of approximately SEK 86m
The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or the "Company") has today, based on the authorizatio ...
Alligator Bioscience launches ALLIGATOR-FAB™ – a novel human antibody library
Lund, Sweden, December 10, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the completion of a novel proprietary human ...